News and price dashboard

SNDK drops 13.5% despite a blowout quarter

Sandisk is the real story on the list today, down 13.5% to $1,150.89 on heavy volume. The quarter itself was huge: fiscal Q1 2027 revenue of $11.03 billion, up 378% year over year and 23% sequentially, non-GAAP EPS of $49.51, GAAP net income of $8.1 billion, data-center revenue of $4.8 billion (up 61% quarter on quarter), and Q2 guidance of $12.2 to $12.6 billion. All of that beat the company's own raised guidance of $10.3 to $10.8 billion and EPS of $44 to $46. Management said roughly 60% of the sequential revenue gain came from higher shipment volumes and 40% from pricing. The stated reason for the selloff is competitor Kioxia: it guided to ¥2 trillion ($12.7 billion) operating profit this quarter against analyst estimates of ¥2.35 trillion, and said NAND average selling prices rose only in the mid-20% range in the September quarter versus 70% the quarter before. That deceleration, plus weak Intel guidance and a broad AI-trade wobble, is what Investing.com cites for the move. Sandisk also announced an 8-for-1 forward split, with split-adjusted trading expected to begin November 20.

Sandisk analyst notes split in both directions

The broker response is mixed rather than uniform. Rosenblatt kept its Buy and left its target at $2,400, Susquehanna cut to $2,720 and Evercore ISI to $2,500, while RBC Capital came down to $1,400 and Wells Fargo all the way to $1,300. Headlines elsewhere frame it as a beat with challenges ahead, and one GuruFocus piece argues the NAND slowdown panic may be overdone. Four TradingView write-ups read in full all take the same starting point, strong earnings against a broken chart: one watches whether $1,100 to $1,150 holds, two set up short entries on a bounce into the $1,150 to $1,400 area with downside targets around $1,025, $1,000 and $905 to $930, and the fourth notes the break below the $1,242 to $1,287 support zone that previously held. These are individual traders' personal setups, not research, and all their levels are pre-split.

OpenWorld down 25% after a dilutive raise

OpenWorld fell 25%. It closed a registered direct offering raising roughly $3.5 million gross, sold to a single institutional investor at-the-market under Nasdaq rules, with Maxim Group as sole placement agent. The deal covered 1,494,084 shares plus pre-funded warrants for 1,023,901 shares, with Series A and Series B warrants each for up to 2,517,985 more shares. Shares were at $0.92, near the $0.91 52-week low, already down 44% over the past week. Officers and directors are locked up for 45 days. Separately, the VerifyMe merger deadline has been extended a third time, to October 31, 2026, with VerifyMe shareholders having approved the share issuance. The matching SEC 8-K on the list is headline-only but covers the same agreement.

Butterfly Network and the rest of the decliners

Butterfly Network is down 14.9%. The only item is a Form 144 filed October 31, and the article carries no detail beyond the filing itself, so there is no stated reason for the move here. Below that, the losses are a cluster of AI-infrastructure and semi names with no company-specific news attached in the list: Datadog down 11.5% (headlines point to the broad tech selloff, plus a Form 4 showing CTO Alexis Le-Quoc selling $12.06 million of class A stock, and option activity), Tower Semiconductor down 11.4% ahead of Q3 earnings, Coherent down 11.3% with Morgan Stanley cutting to $325 and another house to $262, Astera Labs down 10.9%, Nebius down 10.4% with a director buying 148 shares, NetApp down 8.8%, Credo down 8.7%, Arista down 8.3%, Micron down 5.3%, Broadcom down 5.5% (D.A. Davidson upgraded to Buy with a $400 target), TSMC down 5.9%, Oracle down 6.4%, Vertiv down 5.5%, and SpaceX down 6.4%. A DeItaone post on the list tallies peak drawdowns across these names, with Broadcom cited at -31.9% and SpaceX at -31.2% from their 2026 highs.

Small set of gainers and quieter names

Kosmos Energy is up 6.3% ahead of November 2 Q3 results. Stagwell is up 5.2%, with Wells Fargo and B. Riley both raising targets to $12 and an 8-K/A on officer changes. Exelixis is up 4.8% on five target raises the same day, from TD Cowen to $76, Morgan Stanley and Truist to $60, RBC to $58 and Barclays to $54. Accenture is up 4.5%, Comcast 4.3%, Incyte 3.1% on its own cluster of notes including an Oppenheimer upgrade to Outperform at $144. Apple is down just 1.2% and dominates the list by item count, but most of those are unrelated BlackRock and Amundi 13F headlines filed under the ticker; the Apple-specific items are the pre-earnings pieces, the Alibaba Qianwen integration, and Apple retaking the most-valuable-company title from Nvidia. PayPal, Netflix, Adobe and Costco are all effectively flat.

OpenWorld raises $3.5m, stock down a quarter

OpenWorld is down 25% and the reason is on the tape. The company closed a registered direct offering on Friday, roughly $3.5 million gross before fees, sold to a single institutional investor through Maxim Group as sole placement agent on a best-efforts basis. The structure: 1,494,084 common shares plus pre-funded warrants for 1,023,901 shares, with Series A and Series B warrants each covering up to 2,517,985 additional shares. Priced at-the-market under Nasdaq rules, off the Form S-3 shelf that went effective in February 2025. The company and its officers and directors are locked up for 45 days. Investing.com notes the stock was at $0.92 against a 52-week low of $0.91 and down 44% over the prior week, so the raise landed into an already broken price. Context from the same piece: VerifyMe shareholders have approved the merger that would make OpenWorld a wholly owned subsidiary, and the deadline was extended a third time to October 31, 2026. Two SEC 8-K headlines are also in the list, one of which flags Item 3.01, notice of delisting or failure to satisfy a continued listing standard, alongside unregistered sales of equity. That 8-K is headline-only, so the detail behind the listing item isn't in what I've read.

SanDisk down 13.5% on Kioxia NAND warning

SanDisk is the busiest name here, down 13.5% to $1,150.89, and the fall came the day after a very strong quarter. September-quarter revenue was $11.03 billion with adjusted EPS of $49.51, beating its own raised guidance of $10.3–10.8 billion and $44–46. Revenue was up 378% year over year and 23% sequentially, with management attributing about 60% of the sequential gain to volume and 40% to pricing. Data-center revenue rose 61% quarter over quarter to $4.8 billion, GAAP net income was $8.1 billion, Q2 guidance is $12.2–12.6 billion, and the company announced an 8-for-1 forward split with adjusted trading expected to start November 20. The stated trigger for the selloff is Kioxia: it guided to ¥2 trillion ($12.7 billion) operating profit against analyst estimates of ¥2.35 trillion, implying almost flat quarter-on-quarter NAND pricing, and said its average NAND selling price rose in the mid-20% range in the September quarter versus 70% the quarter before. Investing.com also cites weak Intel guidance and general AI-trade nerves. Intel, in the same page's movers table, was down 28.58%.

SanDisk analyst and chart reaction

The sell-side response split. Rosenblatt kept a Buy with the target at $2,400, while Wells Fargo cut to $1,300, RBC Capital to $1,400, Susquehanna to $2,720 and Evercore ISI to $2,500, all maintains with lower targets. Four TradingView posts I read are all watching the same breakdown: the $1,242–$1,287 shelf has been lost and retested from below, and the authors frame $1,100–$1,150 as the immediate test, with $1,025, $1,000 and $905–930 named as the next levels down and $1,300–$1,400 as the line that would invalidate the bearish read. These are individual traders' setups, not research, and several of them are padded with Bitget referral promotion, so weight accordingly. All their levels are pre-split. One GuruFocus headline takes the other side, arguing the NAND slowdown panic may be overdone.

Butterfly Network down 14.9%, no substance behind the item

Butterfly Network is down 14.9%, but the only full-text item on it is an Investing.com stub for a Form 144 filing dated 31 October with no detail beyond the headline itself. Nothing in the material explains the move. If you care about this one, the filing is where to go.

The broader AI and memory complex sold off

Most of the rest of the watchlist moved with the same tape. Datadog fell 11.5%, with GuruFocus tying it to a broad tech selloff on October 30 and separate headlines noting CTO Alexis Le-Quoc sold $12.06 million of class A stock and that the stock carries a maintained Buy ahead of Q3 earnings. Tower Semiconductor dropped 11.4% going into its Q3 report, Coherent 11.3% with Morgan Stanley cutting its target to $325 and another firm trimming to $262, Astera Labs 10.9%, Nebius 10.4% on what GuruFocus attributes to AI cloud expansion concerns, NetApp 8.8%, Credo 8.7%, Arista 8.3%, TD Synnex 7.2%, Taiwan Semi 5.9%, Broadcom 5.5%, Vertiv 5.5% and Micron 5.3%. Oracle lost 6.4%, with headlines on its funding ceiling excluding debt refinancing and a piece framing the bull and bear case as AI backlog against debt burden. The Investing.com market tables on the pages I read put the Nasdaq proxy down 3.46% on the day, the S&P 500 down 1.82%, VIX up 12.91%, and reference a Nasdaq slide of over 5% for the month, its worst since March 2025.

Space, defence and precious metals names lower

SpaceX-linked SPCX fell 6.4% against an unusually loud headline cluster: a Tesla merger facing a China problem and possible Beijing block, Shotwell saying two million shares will be gifted to children's Trump Accounts, a reported reliance on Anthropic for a third of revenue, a malware incident at SpaceX-owned Cursor affecting up to 5,000 users, and two Investing.com pieces simply asking why the stock is sliding. All headline-only, so I can't tell you which of those actually drove it. Rocket Lab was down 7.4%, Red Cat 8.3% alongside four director Form 4 filings, TeraWulf 8.0% with B. Riley cutting its target to $26, AST SpaceMobile 4.9%. On the metals side AngloGold Ashanti fell 6.2% and Wheaton 5.4%, both flagged as entering oversold territory, consistent with gold futures down 3.63% and silver down 6.20% on the day per the quote tables.

The green side of the board

Kosmos Energy rose 6.3% ahead of Q3 results due November 2 before the open. Stagwell gained 5.2% with Wells Fargo, B. Riley and Needham all raising targets to $12.00, plus an 8-K/A on officer departure and compensatory arrangements. Exelixis added 4.8% behind a clean sweep of target raises, TD Cowen to $76, Morgan Stanley and Truist to $60, RBC to $58 and Barclays to $54. Accenture was up 4.5% and Comcast 4.3%. Incyte rose 3.1% with Oppenheimer upgrading to Outperform at $144 and several target raises, though Wells Fargo went the other way to $127. PayPal was flat after a Q3 beat and raised 2026 EPS guidance.

Low-signal items

A large block of the list is GuruFocus 13F-style notes on BlackRock and Amundi position changes in unrelated names, tagged to Apple but with nothing to do with it. Apple itself was down 1.2%, and the headlines there are mostly earnings-preview chatter plus notes that it overtook Nvidia as the most valuable company and that Bank of America lowered its iPhone forecast on a staggered launch. Netflix, Adobe, PayPal and Avery Dennison were essentially unchanged.

OpenWorld down 25% on an 8-K with delisting language

The biggest mover on the list is OpenWorld, off 25%. The full-text item from Investing.com is just a stub announcing the 8-K filing for 30 October with no detail in the body, so there's no explanation there. The companion SEC EDGAR headline does list the filing's items, and they are worth noting: entry into a material definitive agreement, notice of delisting or failure to satisfy a continued listing rule, unregistered sales of equity securities, Reg FD disclosure, and financial statements and exhibits. Nothing in the material explains the terms behind any of those, but the combination of a listing-standard notice and unregistered equity sales is the only concrete thing attached to a quarter-off day. If you hold this, the filing itself is the thing to read.

SanDisk down 13.5% despite a large earnings beat

SanDisk is the most heavily covered name here and fell 13.5%, closing around $1,151.60 on 16 million shares. The earnings were strong: September-quarter revenue of $11.03 billion and adjusted EPS of $49.51, both above the company's own raised guidance of $10.3 to $10.8 billion and $44 to $46. Revenue rose 23% sequentially and 378% year on year, with management attributing about 60% of the sequential gain to volume and 40% to pricing. Non-GAAP gross margin was 85.1% against 84.6% in the prior quarter, data centre revenue rose 61% sequentially to $4.8 billion and is now close to 45% of the total, adjusted free cash flow was $5.7 billion, and there was another $5 billion of buybacks in the quarter. December-quarter guidance is $12.2 to $12.6 billion of revenue and $55 to $57 EPS, with gross margin of 84.5% to 85.5% despite component-cost inflation. The board approved an 8-for-1 stock split distributed 19 November. Non-binding memorandum purchase orders stand at $88.9 billion, down from $91 billion previously, covering half of fiscal 2027 bits and two-thirds of fiscal 2028.

What pushed SanDisk down: Kioxia's NAND pricing signal

The stated trigger for the fall is Kioxia. The Tokyo competitor guided to ¥2 trillion ($12.7 billion) of operating profit this quarter against analyst estimates of ¥2.35 trillion, implying nearly flat quarter-on-quarter price increases, and said its NAND average selling price rose in the mid-20% range in the three months to September versus a 70% rise the quarter before. Investing.com also cites weak Intel guidance and general nerves about the AI trade as contributors. That fits the wider tape in the same articles: Intel was down 28.6%, Nasdaq off 2.86% on the day and heading for its worst month since March 2025, VIX up 13%, with AMD down 10.9%, Qualcomm 11.1%, Dell 10.8% and Micron 5.3%.

The analyst cluster on SanDisk, all cuts, all still constructive

Six separate price-target changes landed, every one of them downward and none of them a downgrade. Mizuho went to $1,900 from $2,050, keeping Outperform, flagging December gross margin guided down roughly 10 basis points to around 85.0% and December revenue of $12.4 billion against $12.5 billion consensus, while valuing the stock at about 8 times fiscal 2027 earnings versus the SOX at roughly 17. Goldman Sachs cut to $2,000 from $2,200 on valuation, keeping Buy, pointing to multiple eSSD wins at hyperscalers and limited NAND supply additions ahead. BofA also went to $2,000, from $2,500, Buy maintained, lowering its target multiple for late-cycle valuation concerns while citing AI inference making NAND more indispensable. Headline-only notes show RBC Capital cutting to $1,400, Susquehanna to $2,720 and Evercore ISI to $2,500. Note the spread there, $1,400 to $2,720, which is unusually wide for the same quarter. Two TradingView posts and a GuruFocus piece titled "Why The Panic Over A NAND Slowdown May Be Overdone" cover the technical and sentiment side; the TradingView items are individual traders' chart setups around the $1,200 level, not research.

Datadog, Coherent, Astera and the rest of the semi and AI-infrastructure complex

Below SanDisk, the losses run along the same line. Datadog fell 11.5% with only headline items, a Rosenblatt reiteration ahead of earnings and a Buy rating maintained, nothing explaining the move. Tower Semiconductor was down 11.4% ahead of Q3 results, Coherent 11.3% with Morgan Stanley cutting to $325 and another firm to $262, Astera Labs 10.9%, Nebius 10.4% (it reports Q3 on 12 November), NetApp 8.8%, Credo 8.7%, Arista 8.3% and TeraWulf 8.0%, where B. Riley trimmed its target to $26. Oracle fell 6.4%, with Investing.com running both a "why is Oracle sliding" piece and one on its AI backlog meeting its debt burden, plus a separate note that Alphabet dropped 12% on capex. Broadcom was off 5.5%, Taiwan Semi 5.9%, Micron 5.3%. None of these were read in full, so treat the attributions as headline-level only.

SpaceX headline cluster

SPCX fell 6.4% with a dense run of headlines and no full text: a Cursor malware incident said to affect up to 5,000 users, a Binance hack story referencing a SpaceX stake, two Investing.com pieces on why Beijing could block the SpaceX-Tesla merger, and one claiming SpaceX relies on Anthropic for a third of its revenue. A separate X post lists SPCX down 31.2% from its June 2026 peak, alongside AVGO at -31.9%, GOOGL -30.4%, MU -26.1% and META -21.5%.

The green side: Stagwell, Exelixis, Incyte, Kosmos

Gains were modest and mostly biotech and small-cap. Kosmos Energy rose 6.3% ahead of 2 November Q3 results. Stagwell was up 5.2% with Wells Fargo, B. Riley and Needham all raising to $12.00 and an 8-K/A on officer departures and appointments. Exelixis gained 4.8% after Q3, with Morgan Stanley, Truist and BMO all going to $60, RBC to $58 and Barclays to $54. Incyte rose 3.1% on an Oppenheimer upgrade to Outperform with a $144 target, raised fiscal 2026 revenue guidance, and target rises from RBC ($117), Barclays ($143) and Evercore ($127), with Wells Fargo cutting to $127 against the grain. Accenture was up 4.5%, mostly on fund-flow and commentary items rather than company news.

Quiet names and noise

Apple was down only 1.2% but carries by far the most items, nearly all of them GuruFocus 13F and ETF-flow summaries about BlackRock and Amundi positions in unrelated companies, which have nothing to do with Apple. The genuine Apple content is headline-level: BofA lowered its iPhone forecast on staggered launch concerns while separately arguing Wall Street may be misreading the stock, UBS reiterated neutral on iPhone wait times, and earnings are imminent. Netflix, PayPal, Adobe, Axsome, Joby and SoundHound all moved less than 3.5% with routine headlines behind them. One macro item is in the list: Q3 employment cost index +0.8% against +0.8% consensus, down from +0.9% in Q2, with wages at +0.7% and benefits +0.9%.

SanDisk falls 9% despite a big earnings beat

SNDK is the main event today, down 9.0%, and it's the one name here with real depth behind it. Fiscal Q1 2027 revenue was $11.0 billion against consensus near $10.7 billion, with non-GAAP EPS of $49.51 versus $47.15 expected, up 23% sequentially and 378% year over year. Data center revenue hit $4.8 billion, up 61% from the prior quarter, now roughly 45% of the business, on AI storage demand. Non-GAAP gross margin was 85.1%, operating margin 80.4%, adjusted free cash flow $5.7 billion, and the company bought back 3.2 million shares for $5.0 billion with zero debt. December-quarter guidance is $12.2 to $12.6 billion of revenue and $55 to $57 EPS, bracketing consensus, plus an 8-for-1 stock split distributing November 19 with split-adjusted trading from November 20. Investing.com's "why is it sliding" piece lays out what investors actually focused on: sequential growth decelerating from 51% to 23%, doubt over whether an 85% gross margin is a peak, a consumer segment down 29%, insiders selling nearly 78,000 shares worth over $121 million in 90 days, and a weak tape. The stock is roughly 46% below its 52-week high of $2,354.39.

Three price target cuts on SanDisk, all keeping Buy

The sell side trimmed targets while leaving ratings alone. BofA went to $2,000 from $2,500, citing late-cycle valuation concerns while still pointing to AI inference making NAND more indispensable. Goldman Sachs cut to $2,000 from $2,200 on valuation, noting multiple eSSD wins at hyperscalers and expecting buybacks to edge higher. Mizuho went to $1,900 from $2,050 on the margin outlook, flagging December gross margin guided down about 10bp to around 85.0% and non-binding memorandum purchase orders of $88.9 billion, down from $91 billion prior, covering half of fiscal 2027 bits and two-thirds of fiscal 2028. Canaccord's note was more upbeat, highlighting the data center surge and that Amazon, Alphabet and Microsoft have all signalled higher AI spending into 2027 and 2028. On the call, management said customers have underestimated how much NAND they need and multiple are coming back for a second round, and that about 95% of NBM counterparties are investment grade. Two TradingView technical pieces frame $1,200 as the level that matters; both are chart opinion, not news.

The sector backdrop behind the drop

The same Investing.com article that explains SanDisk also gives the wider context: Intel plunged 26% on a weak Q4 forecast, the Nasdaq fell 2.2% and the S&P 500 1.0%, with investors questioning AI infrastructure spending durability after Alphabet's capex-driven selloff. That shows up across your list. Micron is down 5.1%, Taiwan Semi down 3.6%, Broadcom down 4.1%, Astera Labs down 7.0%, Credo down 7.6%, Arista down 6.3%, Vertiv down 5.0%, Amphenol down 3.6%, Oracle down 4.5%, Datadog down 4.8%. None of those carry full-text items, so I can't tell you anything beyond the headlines, but the cluster is clearly one trade rather than twenty separate stories. Worth noting the oddity that several of these fell despite positive analyst flow in the headlines: Vertiv has target raises from Bernstein ($376), RBC ($351), Citi ($362) and TD Cowen ($357), and Amphenol has raises to $115 from JPMorgan, Citi and BNP Paribas and to $111 from UBS.

Other notable decliners

Vicor is down 8.6%, Nebius down 8.2% with a headline noting Q3 results due November 12 and a director buying 353 shares, Modine down 7.9% with B. Riley keeping Buy but cutting its target to $285, and Butterfly Network down 7.5% with Q3 earnings call coverage. Iovance is down 4.5% on the quote, but one headline states shares dropped 34% after Phase 2 lung cancer trial results, with an 8-K filed alongside it. Eos Energy is down 6.6% with three filings around CCO Michelle Buczkowski selling $100,000 of stock. VNET is down 6.2% after UBS cut its target to $6.80 on chip delays. Rocket Lab is down 5.8%, with a Form 4 filed. SPCX is down 4.5%, with headlines on a Bloomberg report that Anthropic accounts for over a third of its Q3 revenue and speculation Beijing could block a SpaceX-Tesla merger.

Biotech on the green side

Incyte is up 2.8%, the best gainer here, with raised fiscal 2026 revenue guidance, an Oppenheimer upgrade to Outperform with a $144 target, and an H.C. Wainwright reiteration on cancer trial progress. Exelixis is up 2.7% after beating Q3 estimates, EPS $0.85 on revenue of $658.7 million, with BMO raising its target to $60 on the opex outlook, though one headline notes the stock edged lower on guidance.

Quiet elsewhere

The rest is mostly ETF flow notes, routine Form 4s and earnings-call transcript listings with little movement behind them. Apple is down 0.6% amid a wall of ETF-flow headlines, a UBS neutral reiteration on iPhone wait times, and an $823,720 insider sale by SVP Jennifer Newstead. Costco is up 1.8%, Netflix up 1.0% on a PUBG live-action series with Donald Glover, Stagwell flat at a 52-week high. Nothing there needs a second look today.

Iovance collapses on lung cancer data

IOVA is the big one today, down 35.4% after the Phase 2 lung cancer webcast. The actual numbers: IOV-LUN-202 showed a 24.6% objective response rate in 69 previously treated non-squamous metastatic NSCLC patients, 17 responses in total (15 confirmed, two unconfirmed partials), data as of October 14. A retrospective subgroup of KRAS wild-type, HER2 wild-type patients with current or former smoking history, 22 of the 69, hit a 59.1% response rate and accounted for 13 of the 17 responses. KRAS wild-type overall responded at 43.3% versus 11.4% for KRAS-mutant, and both complete responses were in KRAS wild-type tumors. Iovance plans to start enrolling POSITILITY, a biomarker-enriched registrational-intent cohort, in November 2026, with a supplemental BLA targeted for 2027 and a frontline trial, OPTILISM, also in 2027. Investor's Business Daily pinned the selloff on durability: the company did not say how long patients responded, nor did it give specific safety and tolerability results, and the stock undercut its 50-day line. Investing.com frames it as buy-the-rumor-sell-the-news, noting the stock had risen about 12% after hours on October 28 on a release that carried no efficacy figures at all, then fell 8.9% pre-open; it adds that at roughly $7 billion the company trades near 17 times the midpoint of 2026 revenue guidance, and that the hold-and-hawkish Fed plus a weak Nasdaq hurt long-duration biotech. Q3 earnings are November 5.

Aurora cuts revenue guidance, three targets come down

AUR fell 13.5%. Q3 2026 revenue came in at $3 million, in line with expectations, EPS a loss of $0.12 as estimated, but the operating loss was $257 million and the production schedule is running six weeks late. Full-year 2026 revenue guidance was cut to roughly $9 million from a prior $14 to $16 million, and the target of more than 200 driverless Generation 2 trucks slipped from year-end to end of February. Cash burn is set to rise. Against that, Aurora reaffirmed over 1,000 autonomous trucks by end-2027 at roughly $200 million revenue, more than 7,500 in 2028, and more than 30,000 by 2030 at over $5 billion revenue and a targeted gross margin above 60%; it has more than 20 trucks built and wants 20 a week by early December, with about 500,000 fully driverless miles logged since commercialization began in late April 2025. Three cuts landed on the same day: Cantor Fitzgerald to $11 from $12 (Overweight kept), Needham to $10 from $13 (Buy kept, citing a lower multiple on longer-dated growth given rates), and Goldman Sachs to $6 per a headline-only item.

Stagwell at a 52-week high on record margins

STGW rose 12.7% and touched a 52-week high of $9.64, market cap about $2.16 billion, with a one-year total return of 85.9% and 80.6% year to date. Q3 net revenue was $664 million, up 7% organically, the best in seven quarters; adjusted EBITDA $145 million, up 25%, with margin up 290 basis points to 21.8%; adjusted EPS $0.34 against a $0.31 consensus, up 42%. Total revenue of $816 million missed the $838.44 million expected. The mix shift is the story: Digital Transformation grew 23% organically and The Marketing Cloud 108%, together now 26% of net revenue, while traditional Marketing Services fell 7.5% and Media & Commerce 2.1%; Communications grew 20% on US midterm activity. Enterprise technology has $59 million committed year to date against an initial $25 million target, and the 2027 bookings goal was raised to $150 million from $75 million, tied to work with ServiceNow, Adobe and Palantir. Net new business was $168 million in the quarter and $586 million over twelve months, up 24%, including the largest-ever multi-agency engagement (ServiceNow) and a first major federal contract with US Central Command. Net leverage 2.7x, liquidity $542 million, $326 million left on the buyback, share count down 10 million year over year. Guidance was raised. Mark Penn's line was that Stagwell is becoming "the #1 Marketing Transformation company in the world."

AI infrastructure names caught in the Microsoft read-across

NBIS fell 5.7%, with two headlines tying it and CoreWeave to Microsoft's earnings, one of them referring to a "Microsoft surprise." That's all the headlines state. A separate headline notes director Arne Grimme bought 353 shares. SNDK was down 5.3% despite headlines saying it cleared fiscal Q1 targets, guided higher and announced an 8-for-1 stock split; transcript quotes have the CFO putting data center revenue at $4.8 billion, up 61% sequentially with three US hyperscalers behind it, and the CEO describing a structural increase in NAND demand extending beyond fiscal 2030. One headline flags the stock down about 2% after hours, another has Micron and SanDisk falling as a Samsung selloff hit memory names. WULF was down 5.0% and DDOG 4.5%, both with headline-only items that don't explain the moves.

Oracle slips after its analyst day rally

ORCL fell 3.4% today, which sits awkwardly against a thick cluster of headlines describing a 10-11% surge after its analyst day on an accelerated free cash flow timeline, AI chip strategy and AI partnerships that eased financing worries. Today's headlines point the other way: a decline tied to a $20 billion financing ceiling, and a Scotiabank price target trim. Targets elsewhere were held, not cut: TD Cowen at $240, Oppenheimer at $275, Piper Sandler at $225, with Melius reiterating Buy on the AI infrastructure path. Worth a look if you hold it, since the analyst-day enthusiasm and today's move are pulling in opposite directions.

Earnings and analyst notes across the rest

BFLY was down 3.8% on Q3 revenue of $32.6 million, with one headline calling it an earnings beat with strong revenue growth. MOD fell 3.3% as B. Riley kept a Buy but lowered its target to $285. XENE rose 3.3%, with a headline saying it is advancing pain drugs into Phase 2. Elsewhere the analyst flow leaned positive: Amphenol (+1.4%) had target raises from BNP Paribas to $115, UBS to $111 and Truist to $112 after record Q3 results, though one headline says it lowered Q4 adjusted EPS guidance; Vertiv (+1.2%) had TD Cowen to $357 and Wells Fargo to $345, with Q3 sales up 61%; Generac (+1.0%) drew four raises, Barclays $281, Stifel $325, Needham $288 on data center growth, and Jefferies reiterating Buy at $279. Going the other way, PayPal (+0.7%) was downgraded by Barclays with the target cut to $53 on slowing checkout growth, and UBS trimmed to $60. Jefferies downgraded KOS (-2.9%) while raising its target to $2.90, and Maxim Group cut DVLT (-8.9%) to Hold. Marathon Petroleum (-1.9%) raised its quarterly dividend 10% to $1.10.

Quiet names and unexplained movers

CELU was down 9.7% with only an 8-K covering Item 8.01 Other Events to go on, so there's no stated reason in the material. Avery Dennison (+0.8%) beat on earnings and revenue with Q3 net sales of $2.3 billion, Pagaya (+1.7%) beat with revenue of $390 million versus $382.72 million expected and raised full-year net income guidance, Exelixis (-0.1%) beat by $0.07 on a revenue topper, and Incyte (-0.1%) reported revenue of $1.56 billion ahead of estimates while missing EPS by $0.07, with core business up 37%. Apple rose 1.5% amid a large volume of ETF-flow and chart items with no real news behind them. The remainder of the list is routine filings, index-fund rebalancing notes and commentary that doesn't need your time.

Iovance drops 28% on lung cancer data

IOVA is down 28.2%, and the full data release explains it. Iovance reported a 24.6% objective response rate for lifileucel in 69 previously treated non-squamous metastatic NSCLC patients from the Phase 2 IOV-LUN-202 trial, data as of October 14: 17 responses, 15 confirmed and two unconfirmed partial. The standout was a retrospective subgroup of KRAS wild-type, HER2 wild-type patients with current or former smoking history, 22 of the 69, which showed a 59.1% response rate and accounted for 13 of the 17 responses. KRAS wild-type patients overall responded at 43.3% versus 11.4% for KRAS-mutant, and both complete responses were in KRAS wild-type tumors. The company will start enrolling POSITILITY, a biomarker-enriched registrational-intent cohort, in November 2026, plans a supplemental BLA in 2027, and intends to start a frontline trial, OPTILISM, in 2027. Investing.com's separate piece frames the move as buy-the-rumour, sell-the-news: the stock had risen about 12% after hours on October 28 on the headline announcement, which carried no efficacy figures, then reversed into the webcast. That article also notes a roughly $7 billion market value, near 17 times the midpoint of 2026 revenue guidance for a company not yet profitable, cites the Fed's October 28 hold at 3.75–4% with two dissents wanting a hike, higher long-end yields, and a weak Nasdaq as added pressure on long-duration biotech. Q3 earnings are November 5.

Vertiv up 16.5% on Q3 beat and raise

VRT is up 16.5% after Q3 2026 adjusted EPS of $2.21 against a $1.82 estimate on revenue of $4.31 billion versus $3.75 billion expected, sales up 61% year on year, with adjusted operating margin of 25.2%, up 290 basis points. Organic orders grew more than 100%, and CEO Gio Albertazzi said "we are not talking about catch-up here," with the Americas pipeline growing at its fastest sequential pace this year and EMEA roughly doubling. Full-year guidance went up: net sales to $14.65 billion (+$650 million), adjusted EPS to $7.15 (+$0.45), operating profit above $3.5 billion, margin to 24%. Q4 is guided to about $4.4 billion revenue and $2.25 EPS at the midpoint, modestly above the $2.21/$4.31 billion consensus. Open questions flagged in the analysis: uneven execution (Q2 revenue missed, Q4 FY2025 EPS missed by 12.3%), capacity expansion risk in Slovakia, Ireland and the Americas, and no 2027 guidance yet. Wells Fargo lifted its target to $345 from $340 with an Overweight, saying Q3 unwound the execution worries that built up after Q2, that it found no evidence of product ramp issues, and that the Q4 margin target of 26% is already close to the 27% 2030 goal. The GuruFocus headlines on the surge, the raised guidance and the order growth all point at the same release.

Oracle up 10.7% after Investor Day

ORCL is up 10.7% on the back of its Investor Day. The company set a fiscal 2030 revenue target above $225 billion, implying over 35% annualised growth, with free cash flow turning positive in the second half of fiscal 2028 and exceeding $30 billion by 2029 as capex starts declining. Crucially for the debt worry, Oracle said it will cap additional financing through fiscal 2030 at $20 billion, split evenly between debt and equity. Melius reiterated Buy with a $170 target, noting the free cash flow turn comes about a year earlier than it had assumed, that FY2027 and FY2028 are peak capex years, and that management expects to add roughly 7 gigawatts of capacity to reach about 10 gigawatts by end of FY2028, with OCI benefiting from more OpenAI business and from offering Google's TPU, Cerebras and Nvidia's Vera Rubin. The $170 target is 10 times Melius's FY2029 EPS estimate of $16.76. Headline-only items add that Piper Sandler kept its $225 target, that FY2027 revenue of $90 billion was reaffirmed, and separate pieces on Google opening its AI chips to Oracle and Nvidia Vera CPUs landing on Oracle Cloud. The TradingView piece ties Oracle's cash flow promise to Microsoft actually delivering, with Azure revenue up 48% and free cash flow of $18.6 billion.

Smaller movers with earnings behind them

Butterfly Network is down 8.8% despite headlines saying Q3 beat, with revenue of $32.6 million. Nebius is up 7.0%, though the only item is a headline asking why CoreWeave and Nebius are sinking after Microsoft earnings, so the headline and the quote point opposite ways. TeraWulf up 6.0% and Micron up 5.9% have only commentary and valuation-screen headlines attached, nothing substantive. Incyte is down 4.8% after Q3 revenue of $1.56 billion that topped estimates while EPS missed by $0.07. Aurora Innovation is down 4.7% after reporting Q3 revenue of $3 million and an operating loss of $257 million, with headlines citing driverless fleet expansion alongside production delays. Stagwell is down 4.2% on record Q3 revenue of $816 million but EPS of $0.07 against a $0.26 estimate.

Analyst notes and quiet names

PayPal, up 0.8%, drew a cluster of notes: Barclays cut its rating on slowing checkout growth, UBS lowered its target to $60 and Citigroup to $58, while BMO raised to $59 and TD Cowen to $60. Generac is flat but had Needham raise to $288 on data centre growth, Jefferies reiterate Buy at $279, and a record Q3 with a $2.4 billion Amazon supply deal. Marathon Petroleum, up 1.3%, raised its quarterly dividend 10% to $1.10. Apple is up 1.1% with product news, the new M6 MacBook Pro and iMac including a touchscreen notebook, Macs set for November 6, plus a Bernstein SocGen Outperform reiteration on share gains. Avery Dennison, down 0.6%, beat on earnings and revenue. SpaceX is down 1.8%, with headlines on a lawsuit over the tax deal behind its $100 billion Louisiana project and Alphabet's CFO attributing a negative $8.2 billion in other income largely to an unrealised loss on its SpaceX stake. The rest of the list, including the long run of Planet MicroCap Showcase items tagged to PL, is ETF flow noise, routine 8-Ks and earnings calendar entries with no real movement behind them.